5-ethoxy-1-phenyl-1H-pyrazole-4-carboxylic acid ethyl ester | 706819-80-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-ethoxy-1-phenyl-1H-pyrazole-4-carboxylic acid ethyl ester
• 英文别名: ethyl 5-ethoxy-1-phenyl-1H-pyrazole-4-carboxylate；Ethyl 5-ethoxy-1-phenylpyrazole-4-carboxylate
• CAS: 706819-80-9
• 化学式: C₁₄H₁₆N₂O₃
• 分子量: 260.293
• InChiKey: VNXJDBNOMJOGFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  53.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-ethoxy-1-phenyl-1H-pyrazole-4-carboxylic acid ethyl ester 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以83%的产率得到5-ethoxy-1-phenyl-1H-pyrazole-4-carboxylic acid
  参考文献：
  名称：

  A novel series of potent and selective small molecule inhibitors of the complement component C1s

  摘要：

  Activation of the classical pathway of complement has been implicated in disease states such as hereditary angioedema, ischemia-reperfusion injury and acute transplant rejection. The trypsin-like serine protease C1s represents a pivotal upstream point of control in the classical pathway of complement activation and is therefore likely to be a useful target in the therapeutic intervention of these disease states. A series of thiopheneamidine-based inhibitors of C1s has been optimized to give a 70 nM inhibitor that inhibits the classical pathway of complement activation in vitro. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.034
• 作为产物：
  描述：

  乙醇 、 3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid ethyl ester 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 以68%的产率得到5-ethoxy-1-phenyl-1H-pyrazole-4-carboxylic acid ethyl ester
  参考文献：
  名称：

  A novel series of potent and selective small molecule inhibitors of the complement component C1s

  摘要：

  Activation of the classical pathway of complement has been implicated in disease states such as hereditary angioedema, ischemia-reperfusion injury and acute transplant rejection. The trypsin-like serine protease C1s represents a pivotal upstream point of control in the classical pathway of complement activation and is therefore likely to be a useful target in the therapeutic intervention of these disease states. A series of thiopheneamidine-based inhibitors of C1s has been optimized to give a 70 nM inhibitor that inhibits the classical pathway of complement activation in vitro. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.034

文献信息

• 5-Iodo-3-Ethoxypyrazoles: An Entry Point to New Chemical Entities
  作者：Sandrine Guillou、Yves L. Janin

  DOI：10.1002/chem.200903442

  日期：2010.4.19

  focused on the preparation of new pyrazole derivatives, has led us to report here an original and simplified preparation of ethyl 3‐ethoxy‐1H‐pyrazole‐4‐carboxylate. This is based on the reaction of hydrazine monohydrochloride and diethyl 2‐(ethoxymethylene)malonate. Further transformations of this key compound allowed the preparation of the two possible iodinated isomers, namely, 3‐ethoxy‐4‐iodo‐ and

  我们的计划侧重于制备新的吡唑衍生物，使我们在此报告了3-乙氧基-1 H-吡唑-4-羧酸乙酯的原始且简化的制备方法。这基于肼一盐酸盐和2-（乙氧基亚甲基）丙二酸二乙酯的反应。该关键化合物的进一步转化使得可以制备两种可能的碘代异构体，即3-乙氧基-4-碘和3-乙氧基-5-碘-1 H吡唑 这些化合物为快速获得许多原始的吡唑系列开辟了道路。作为说明，我们在此报告有关N-芳基化的选择性，方法是使用Lam和Cham方法，通过使用Suzuki-Miyaura反应以及其中一些3-乙氧基吡唑衍生物的C4-C5和C5-芳基化以及C5-苄基化通过根岸反应进行反应。其次是乙氧基的水解，这导致了相应的吡唑-3-酮衍生物。作为这项工作的结论，我们对2-（乙氧基亚甲基）丙二酸二乙酯与甲基，苄基或苯基肼的盐酸盐之间的缩合的区域化学进行了研究。
• Alkoxypyrazoles and the process for their preparation
  申请人：Institut Pasteur

  公开号：EP2151434A1

  公开（公告）日：2010-02-10

  The present invention relates to a process for the preparation of alkoxypyrazoles and new alkoxypyrazole compounds.

  本发明涉及一种制备烷氧基吡唑和新烷氧基吡唑化合物的方法。
• PYRAZOLE-AMINE COMPOUNDS USEFUL AS KINASE INHIBITORS
  申请人：Dyckman J. Alaric

  公开号：US20080108626A1

  公开（公告）日：2008-05-08

  The present invention provides pyrazole derived compounds of formula (I) useful for treating p38 kinase-associated conditions, where G, X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and m are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.
• US7390810B2
  申请人：——

  公开号：US7390810B2

  公开（公告）日：2008-06-24
• US7414056B2
  申请人：——

  公开号：US7414056B2

  公开（公告）日：2008-08-19